Barclays PLC Has $5.69 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Barclays PLC grew its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 141.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 126,675 shares of the company's stock after purchasing an additional 74,130 shares during the period. Barclays PLC owned about 0.29% of Soleno Therapeutics worth $5,694,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AlphaQuest LLC grew its stake in shares of Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after acquiring an additional 658 shares in the last quarter. US Bancorp DE purchased a new stake in Soleno Therapeutics in the 4th quarter valued at about $34,000. Avanza Fonder AB bought a new position in shares of Soleno Therapeutics during the 4th quarter worth approximately $76,000. Springhill Fund Asset Management HK Co Ltd purchased a new position in shares of Soleno Therapeutics in the 4th quarter worth approximately $81,000. Finally, Avior Wealth Management LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter valued at approximately $89,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Patricia C. Hirano sold 3,782 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total value of $265,156.02. Following the completion of the transaction, the insider now owns 27,036 shares in the company, valued at $1,895,493.96. This trade represents a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the company's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares in the company, valued at approximately $39,021,879.12. The trade was a 54.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 942,672 shares of company stock worth $64,058,781 over the last three months. Company insiders own 12.30% of the company's stock.

Soleno Therapeutics Stock Down 1.3 %

Shares of Soleno Therapeutics stock opened at $73.26 on Friday. The company has a market cap of $3.36 billion, a PE ratio of -22.07 and a beta of -2.29. The business has a 50 day moving average of $57.41 and a 200 day moving average of $52.85. Soleno Therapeutics, Inc. has a 52 week low of $36.93 and a 52 week high of $74.50.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41). On average, research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

SLNO has been the topic of a number of research analyst reports. Lifesci Capital raised shares of Soleno Therapeutics to a "strong-buy" rating in a report on Tuesday, February 4th. Laidlaw increased their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Stifel Nicolaus lifted their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. UBS Group set a $105.00 price target on Soleno Therapeutics in a research note on Thursday, March 27th. Finally, Guggenheim reiterated a "buy" rating and issued a $81.00 price objective (up from $70.00) on shares of Soleno Therapeutics in a research note on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $104.67.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.